RM-131 could bring Rhythm to gastroparesis patients
This article was originally published in Scrip
Executive Summary
Boston-based biotechnology company, Rhythm, is the latest company to try and pave the way for ghrelin agonists in treating gastrointestinal disorders having started Phase I trials for RM-131 in "gastroparesis and other functional GI disorders", including diabetic gastroparesis and postoperative ileus.